Financial Reports 2021

Quarterly Report Q2 2021

Issue link: https://liminalbiosciences.com/resources/i/1403149

Contents of this Issue

Navigation

Page 47 of 47

LIMINAL BIOSCIENCES INC. CONDENSED INTERIM FINANCIAL STATEMENTS (In thousands of Canadian dollars) (Unaudited) 47 14. Subsequent events On July 9, 2021, the Company closed the sale of PBP, its plasma Kedrion for US$9.1 million, subject to closing adjustments. On entered into a definitive agreement for the sale of the PRV it FDA approval of it Biologics License Application for Ryplazim ® . Pursuant to the terms of the would receive an upfront payment of US$105.0 million (US$103.5 transaction. The closing is subject to customary closing conditions, clearance requirements. Also, prior to the close of the transaction, by Kedrion, an amount equivalent to 30% of the net proceeds compensation for past services. These transactions are further

Articles in this issue

view archives of Financial Reports 2021 - Quarterly Report Q2 2021